Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy

Journal of Neuroimmunology

Volumn 255, Issue 1-2, 2013, Pages 81-84

  Esendagli, Gunes ^a   Kurne, Asli Tuncer ^a   Sayat, Guliz ^a   Kilic, Ahmet Kasim ^a   Guc, Dicle ^a   Karabudak, Rana ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

IL 17; IL 17R; IL 23; IL 23R; IL 26; Multiple sclerosis

Indexed keywords

BETA1 INTERFERON; CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 26; MICROSOMAL AMINOPEPTIDASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TH17 CELL; TREATMENT DURATION; UPREGULATION;

ADULT; FEMALE; HUMANS; INTERFERON-BETA; INTERLEUKIN-17; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TH17 CELLS; YOUNG ADULT;

EID: 84872656510     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.10.009     Document Type: Article

References (19)

1. Akdis M., Burgler S., Crameri R., Eiwegger T., Fujita H., Gomez E., Klunker S., Meyer N., O'Mahony L., Palomares O., Rhyner C., Ouaked N., Schaffartzik A., Van De Veen W., Zeller S., Zimmermann M., Akdis C.A. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. J. Allergy Clin. Immunol. 2011, 127(701-721):e701-e770.
2. Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., Naves R., Han M., Zhong F., Castellanos J.G., Mair R., Christakos A., Kolkowitz I., Katz L., Killestein J., Polman C.H., de Waal Malefyt R., Steinman L., Raman C. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 2010, 16:406-412.
3. Brucklacher-Waldert V., Stuerner K., Kolster M., Wolthausen J., Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
4. Chen S.J., Wang Y.L., Fan H.C., Lo W.T., Wang C.C., Sytwu H.K. Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin. Dev. Immunol. 2012, 2012:970789.
5. Dhib-Jalbut S., Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010, 74:S17-S24.
6. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 2008, 8:337-348.
7. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 2009, 9:556-567.
8. Jager A., Dardalhon V., Sobel R.A., Bettelli E., Kuchroo V.K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 2009, 183:7169-7177.
9. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
10. Kress-Bennett J.M., Ehrlich G.D., Bruno A., Post J.C., Hu F.Z., Scott T.F. Preliminary study: treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rbeta2+ and decreased levels of IL23R+ CD4+ T-lymphocytes in multiple sclerosis. BMC Neurol. 2011, 11:155.
11. Kurtuncu M., Tuzun E., Turkoglu R., Petek-Balci B., Icoz S., Pehlivan M., Birisik O., Ulusoy C., Shugaiv E., Akman-Demir G., Eraksoy M. Effect of short-term interferon-beta treatment on cytokines in multiple sclerosis: significant modulation of IL-17 and IL-23. Cytokine 2012, 59:400-402.
12. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
13. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 1999, 5:101-104.
14. McGeachy M.J., Cua D.J. The link between IL-23 and Th17 cell-mediated immune pathologies. Semin. Immunol. 2007, 19:372-376.
15. Montes M., Zhang X., Berthelot L., Laplaud D.A., Brouard S., Jin J., Rogan S., Armao D., Jewells V., Soulillou J.P., Markovic-Plese S. Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells. Clin. Immunol. 2009, 130:133-144.
16. Ramgolam V.S., Sha Y., Jin J., Zhang X., Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J. Immunol. 2009, 183:5418-5427.
17. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172:146-155.
18. Wen S.R., Liu G.J., Feng R.N., Gong F.C., Zhong H., Duan S.R., Bi S. Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 2012, 244:94-96.
19. Zhang X., Markovic-Plese S. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. Clin. Neurol. Neurosurg. 2010, 112:641-645.